Suppr超能文献

化疗用完全植入式静脉输液港并发症的临床回顾与分析。

Clinical review and analysis of complications of totally implantable venous access devices for chemotherapy.

机构信息

Department of Cardiovascular and Thoracic Surgery, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Seoul, Korea.

出版信息

Med Oncol. 2012 Jun;29(2):1361-4. doi: 10.1007/s12032-011-9887-y. Epub 2011 Mar 6.

Abstract

Since the first implant of totally implantable venous access device (TIVAD), performed by Niederhuber and colleague in 1982, the systems have increasingly been used in the field of oncology. We analyzed the clinical reviews and complications of TIVAD in an effort to achieve optimal management. We retrospectively studied 442 cases with TIVAD device at our hospital and we report the results. Four hundred and forty-two TIVAD were placed in the right subclavian vein in 345 cases, the left subclavian vein in 93 cases, the right jugular vein in 2 cases, the left jugular vein in 1 case, and the right femoral vein in 1 case. The immediate complications were 28 cases in malposition of the catheter, 10 cases of arterial puncture, and 2 cases of pneumothorax. The late complications were 3 cases of pocket infection, 2 cases of catheter related to sepsis, 3 cases of catheter obstruction, 2 cases of SVC thrombosis, and 1 case of catheter fracture (pinch-off syndrome: Hinke grade 3). There were no other early or late complications. The low rate of complications in the study confirms the safety and convenience of using TIVAD in patients undergoing prolonged chemotherapy. Yet because infection, thrombosis and catheter fracture are the most common long-term complications of TIVAD, early diagnosis and management of these problems can prevent severe complications.

摘要

自 Niederhuber 及其同事于 1982 年首次植入完全植入式静脉通路装置(TIVAD)以来,该系统在肿瘤学领域的应用日益广泛。我们分析了 TIVAD 的临床评估和并发症,以努力实现最佳管理。我们回顾性研究了我院 442 例 TIVAD 患者,并报告了结果。442 例 TIVAD 中有 345 例置入右侧锁骨下静脉,93 例置入左侧锁骨下静脉,2 例置入右侧颈内静脉,1 例置入左侧颈内静脉,1 例置入右侧股静脉。即刻并发症包括导管位置不当 28 例,动脉穿刺 10 例,气胸 2 例。晚期并发症包括 3 例袋部感染,2 例导管相关性败血症,3 例导管阻塞,2 例上腔静脉血栓形成,1 例导管断裂(夹闭综合征:Hinke 分级 3)。无其他早期或晚期并发症。研究中并发症发生率低证实了 TIVAD 在接受长期化疗的患者中使用的安全性和便利性。然而,由于感染、血栓形成和导管断裂是 TIVAD 最常见的长期并发症,早期诊断和处理这些问题可以预防严重并发症。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验